Project Number 5U01AG048310-02 Agency/Funding Organization NIA Funding Year 2016 View Full Project Details for PRE-CLINICAL STUDY TO FULFILL FDA REQUIREMENTS FOR THE COMPLETION OF AV-1959 IND Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) a. Amyloid beta Researcher and Organization Principal Investigator AGADJANYAN, MICHAEL G Principal Investigator First Name MICHAEL G Principal Investigator Last Name AGADJANYAN Awardee Organization INSTITUTE FOR MOLECULAR MEDICINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-12-015: Alzheimer's Disease Drug Development Program (U01) FY Overall Cost $1,174,622 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PETANCESKA, SUZANA Related Resources Repository [AlzPED] MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice [AlzPED] Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
